Article
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Oncotarget - 6 Dec 2016
Suarez-Kelly Lorena P, Kemper Gregory M, Duggan Megan C, Stiff Andrew, Noel Tiffany C, Markowitz Joseph, Luedke Eric A, Yildiz Vedat O, Yu Lianbo, Jaime-Ramirez Alena Cristina, Karpa Volodymyr, Zhang Xiaoli, Carson William E
Abstract excerpt
The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib. Interferon-alpha (IFN-α), an immune boosting agent, is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.